Cost Sharing and Hereditary Cancer Risk: Predictors of Willingness-to-Pay for Genetic Testing

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

(2013) Nasim Mavaddat et al.   JNCI-Journal of the National Cancer Institute

Predictive genetic testing of first degree relatives of mutation carriers is a cost-effective strategy in preventing hereditary non-polyposis colorectal cancer in Singapore

(2012) Vivian Wei Wang et al.   Familial Cancer

Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome

(2012) Grace Wang et al.   Journal of Oncology Practice

A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families

(2011) Kathleen Y. Yang et al.   Familial Cancer

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

(2011) John Burn et al.   LANCET

Interest in Genetic Testing for Modest Changes in Breast Cancer Risk: Implications for SNP Testing

(2011) K.D. Graves et al.   Public Health Genomics

Communicating genetic risk information within families: a review

(2010) Mel Wiseman et al.   Familial Cancer

Spinocerebellar ataxia: Patient and health professional perspectives on whether and how patents affect access to clinical genetic testing

(2010) Ashton Powell et al.   GENETICS IN MEDICINE

Understanding How Out-of-Pocket Expenses, Treatment Value, and Patient Characteristics Influence Treatment Choices

(2010) Y.-N. Wong et al.   ONCOLOGIST

Ten Years After Mutation Testing for Lynch Syndrome: Cancer Incidence and Outcome in Mutation-Positive and Mutation-Negative Family Members

(2009) Heikki J. Järvinen et al.   JOURNAL OF CLINICAL ONCOLOGY